Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
Uboldi S, Bernasconi S, Romano M, Marchini S, Fuso Nerini I, Damia G, Ganzinelli M, Marangon E, Sala F, Clivio L, Chiorino G, Di Giandomenico S, Rocchi M, Capozzi O, Margison GP, Watson AJ, Caccuri AM, Pastore A, Fossati A, Mantovani R, Grosso F, Tercero JC, Erba E, D'Incalci M. Uboldi S, et al. Int J Cancer. 2012 Jul 1;131(1):59-69. doi: 10.1002/ijc.26340. Epub 2011 Aug 30. Int J Cancer. 2012. PMID: 21805478
Mode of action of trabectedin in myxoid liposarcomas.
Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, Gronchi A, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JM, D'Incalci M. Di Giandomenico S, et al. Among authors: uboldi s. Oncogene. 2014 Oct 30;33(44):5201-10. doi: 10.1038/onc.2013.462. Epub 2013 Nov 11. Oncogene. 2014. PMID: 24213580
Mechanism of action of trabectedin in desmoplastic small round cell tumor cells.
Uboldi S, Craparotta I, Colella G, Ronchetti E, Beltrame L, Vicario S, Marchini S, Panini N, Dagrada G, Bozzi F, Pilotti S, Galmarini CM, D'Incalci M, Gatta R. Uboldi S, et al. BMC Cancer. 2017 Feb 6;17(1):107. doi: 10.1186/s12885-017-3091-1. BMC Cancer. 2017. PMID: 28166781 Free PMC article.
Role of macrophage targeting in the antitumor activity of trabectedin.
Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Germano G, et al. Among authors: uboldi s. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008. Cancer Cell. 2013. PMID: 23410977 Free article.
Resistance to minor groove binders.
Colmegna B, Uboldi S, Erba E, D'Incalci M. Colmegna B, et al. Among authors: uboldi s. Drug Discov Today Technol. 2014 Mar;11:73-9. doi: 10.1016/j.ddtec.2014.03.001. Drug Discov Today Technol. 2014. PMID: 24847656
Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
Dossi R, Frapolli R, Di Giandomenico S, Paracchini L, Bozzi F, Brich S, Castiglioni V, Borsotti P, Belotti D, Uboldi S, Sanfilippo R, Erba E, Giavazzi R, Marchini S, Pilotti S, D'Incalci M, Taraboletti G. Dossi R, et al. Among authors: uboldi s. Int J Cancer. 2015 Feb 1;136(3):721-9. doi: 10.1002/ijc.29023. Epub 2014 Jun 19. Int J Cancer. 2015. PMID: 24917554
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents.
Amaral AT, Garofalo C, Frapolli R, Manara MC, Mancarella C, Uboldi S, Di Giandomenico S, Ordóñez JL, Sevillano V, Malaguarnera R, Picci P, Hassan AB, De Alava E, D'Incalci M, Scotlandi K. Amaral AT, et al. Among authors: uboldi s. Clin Cancer Res. 2015 Mar 15;21(6):1373-82. doi: 10.1158/1078-0432.CCR-14-1688. Epub 2015 Jan 21. Clin Cancer Res. 2015. PMID: 25609059
12 results